Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Podobne zapisy

• Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
  od: Fleischmann, Roy, i wsp.
  Wydane: (2016)
• Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
  od: Strand, Vibeke, i wsp.
  Wydane: (2017)
• Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
  od: Strand, Vibeke, i wsp.
  Wydane: (2016)
• Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
  od: Strand, Vibeke, i wsp.
  Wydane: (2016)
• Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
  od: Bergrath, Evelien, i wsp.
  Wydane: (2017)